Rafael Holdings, Inc. (NYSE:RFL) recently had a high trading volume day. The volume for the company on 10-Jan-19 was recorded to be 240374 contracts. Over the past five days, the average daily trading volume came in at about 60040 shares per day. The regular trading started at $9.59 but as the trading progresses, the stock escalated, ending the session with a gain of 30%. Its shares last exchanged hands at a price of $11.83 apiece. The European Medicines Agency (EMA) has granted orphan drug designation to devimistat (CPI-613®), the Company’s lead Altered Metabolism Directed (AMD) drug candidate, for the treatment of older patients (≥ 60 years) with relapsed or refractory Acute Myeloid Leukemia (AML).
AML is a hematologic malignancy characterized by the accumulation of clonal myeloid progenitor cells (“blasts”) in the blood or bone marrow. Malignant hematopoietic stem and myeloid progenitor cells proliferate uncontrollably and disrupt normal hematopoiesis, resulting in impairments in the ability of these myeloid progenitor cells to differentiate. Many patients who achieve a remission and complete consolidation therapy still have a guarded prognosis. This is driven by the fact that over 50% of patients will experience a relapse, and most of them will die from AML within a year. There is no consensus standard treatment for relapsed or refractory disease, but most fit patients are treated with a high dose cytarabine (HiDAC) based regimen.
Devimistat is a first-in-class drug developed based on Rafael’s Altered Metabolism Directed (AMD) platform. Devimistat targets the altered regulation of metabolic processes specific to cancer cells. It is highly specific, simultaneously attacking multiple targets, minimally toxic and has broad spectrum activity across a wide variety of cancers. Devimistat is currently being evaluated in 7 trials as a single agent, as well as in combination with standard drug therapies for hematological malignancies and solid tumors.
To date, over 300 subjects have received one or more doses of devimistat with encouraging response rates and durations of response in several tumor types. In elderly patients with relapsed or refractory AML, devimistat at the biologically effective dose in combination with high dose cytarabine and mitoxantrone exhibited 52% CR+CRi and 12.4 months median overall survival. These results are substantially higher than standard therapy. Devimistat showed a very good safety profile both as single agent and in combination with other standard-of-care drugs. Devimistat has been granted orphan drug designation by the U.S. FDA for Pancreatic Cancer, AML, MDS, Peripheral T-cell Lymphoma and Burkitt’s Lymphoma, and has been granted orphan drug designation by the EMA for Pancreatic Cancer and AML.RFL Is 40.27% Away From SMA20
The shares of the company (RFL) staged the smart recovery as has roared back some 287.87% after stumbling to its new 52-weeks low. The share price volatility of the stock remained at 8.51% for the week and by reducing the timeframe to just a week, the volatility stood at 6.18%. As for the shares, it has gone above the 20 days moving average and is now hovering within a distance of 40.27%. Currently the price is sitting at 40.68% higher than its 50 days moving average. Analyzing the last five market sessions, the stock was able to report 40.83% gains, thus going up by 39.26%, compared with its 200-day moving average. Also, a 0% overturn in Rafael Holdings, Inc. (RFL) witnessed over the past one year demand tendency to limit losses.Jaguar Health, Inc. (NASDAQ:JAGX) Worth Keeping An Eye On
Jaguar Health, Inc. (JAGX) was also brought into the spotlight with a -$0.06 drop. As the regular session came to an end, the price changed by -18.18% to $0.27. The trading of the day started with the price of the stock at $0.3134. However, at one point, in the middle of the day, the price touched a high of $0.3337 before it finally returned some of the gains. Analyzing JAGX this week, analysts seem to be content with keeping to their neutral forecast call at 2. Jaguar Health, Inc. tumbled -95.87% from their most recent record high of $6.6 and now hold $5.82 million in market value of equity.
They expect that Jaguar Health, Inc. (JAGX) price will be reaching a mean target of $1.25 a share. This implies that they believe the stock has what it takes to lift the price another 362.96%. The recent close goes a long way in suggesting that the stock price is being underpriced by a 270.37% compared to the most bullish target.Jaguar Health, Inc. (JAGX) Returns 19.14% This Year
The company during the last trade was able to reach a volume of 1407084 shares. That activity is comparable to their recent volume average trend of nearly 902660 shares which they recorded over a period of three months. Jaguar Health, Inc. price was kept to a minimum $0.27 in intra-day trade and has returned 19.14% this year alone. At a certain point in the past four quarters, the shares traded as low as $0.12 but made a 137.04% recovery since then.